Daiichi Sankyo shutters Indian R&D unit

11 January 2017
daiichi-sankyo-logo-big

Daiichi Sankyo (TYO: 4568) yesterday announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma (DSIN), located in Gurgaon, India, to increase R&D productivity.

The Japanese pharma major says it is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.

DSIN presently employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo’s R&D Division.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical